PR.com: Business Directory, Press Releases, Jobs, Products, Services, Articles
 
Businesses Articles Press Releases Follow @PRcom
Press Release Pricing | News by Category | News by Country | News by US Region | Recent News | PR.com News on Your Site
 

Press Releases

 
iHealthcareAnalyst, Inc.

Press Release


Receive press releases from iHealthcareAnalyst, Inc.: By Email RSS Feeds:

Multiple Sclerosis Treatment Market by Drugs Classes, Geography, Trends and Forecast to 2021, Upcoming Report by iHealthcareAnalyst, Inc.


Multiple Sclerosis Treatment Market by Drug Class (Immunomodulators - Ampyra, Avonex/Plegridy, Betaseron/Extavia, Copaxone, Gilneya, Rebif, Tecifidera, Tysabri; and Immunosuppressants - Aubagio, Lemtrada, Ocrelizumab, Zinbryta) and Forecast 2017-2021.

Maryland Heights, MO, May 06, 2017 --(PR.com)-- Presently, there's no cure for multiple sclerosis (MS), but it's possible to treat the symptoms with medications and other treatments. Treatment typically focuses on speeding recovery from attacks, slowing the progression of the disease and managing MS symptoms. Treatment for MS depends on the specific symptoms and difficulties the person has. It may include: treating relapses of MS symptoms (with steroid medication), treating specific MS symptoms, and treatment to reduce the number of relapses (disease-modifying therapies). Treatment options for relapsing-remitting MS include: Beta interferons are among the most commonly prescribed medications to treat MS and can reduce the frequency and severity of relapses. Glatiramer acetate (Copaxone) may help block your immune system's attack on myelin. Dimethyl fumarate (Tecfidera) can reduce relapses. Fingolimod (Gilenya) and Teriflunomide (Aubagio) oral medications reduces relapse rate. Natalizumab (Tysabri) blocks the movement of potentially damaging immune cells from your bloodstream to your brain and spinal cord. Alemtuzumab (Lemtrada) drug helps reduce relapses of MS by targeting a protein on the surface of immune cells and depleting white blood cells. Mitoxantrone immunosuppressant drug can be harmful to the heart and is associated with development of blood cancers. Therefore, its use in treating MS is extremely limited, and only to treat severe, advanced MS.

Visit Multiple Sclerosis Treatment Market by Drug Class (Immunomodulators - Ampyra, Avonex/Plegridy, Betaseron/Extavia, Copaxone, Gilneya, Rebif, Tecifidera, Tysabri; and Immunosuppressants - Aubagio, Lemtrada, Ocrelizumab, Zinbryta) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/multiple-sclerosis-treatment-market/.

The global multiple sclerosis treatment market segmentation is based on drug class (Immunomodulators - Ampyra, Avonex/Plegridy, Betaseron/Extavia, Copaxone, Gilneya, Rebif, Tecifidera, Tysabri; and Immunosuppressants - Aubagio, Lemtrada, Ocrelizumab, Zinbryta).

The global multiple sclerosis treatment market report provides market size (Revenue USD Million 2014 to 2021), market share, trends and forecasts growth trends (CAGR%, 2017 to 2021). The global multiple sclerosis treatment market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global multiple sclerosis treatment market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.

Major players operating in the global multiple sclerosis drugs market and included in this report are Bayer Healthcare, Biogen Idec, Merck, Novartis, Pfizer, Sanofi-Aventis, and Teva Pharmaceuticals.

1. Drug Class
1.1. Immunomodulators
1.1.1. Ampyra
1.1.2. Avonex/Plegridy
1.1.3. Betaseron/Extavia
1.1.4. Copaxone
1.1.5. Gilneya
1.1.6. Rebif
1.1.7. Tecifidera
1.1.8. Tysabri
1.2. Immunosuppressants
1.2.1. Aubagio
1.2.2. Lemtrada
1.2.3. Ocrelizumab
1.2.4. Zinbryta

2. Company Profiles
2.1. Bayer Healthcare
2.2. Biogen Idec
2.3. Merck
2.4. Novartis
2.5. Pfizer
2.6. Sanofi-Aventis
2.7. Teva Pharmaceuticals

To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/multiple-sclerosis-treatment-market/

About Us
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.

Contact Us
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
Website: https://www.ihealthcareanalyst.com
Contact Information
iHealthcareAnalyst, Inc.
Ana Aitawa
(314) 500-7508
Contact
https://www.ihealthcareanalyst.com/

Click here to view the list of recent Press Releases from iHealthcareAnalyst, Inc.
Promote Your Business